Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
RAS wild-type
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
;
4893
;
3265
Related biomarkers:
Expression
Mutation
CNA
Others
‹
STK11 deletion + KRAS mutation (6)
FGF19 amplification + HRAS Q61R + TP53 672+2T>G (6)
FGF3 amplification + HRAS Q61R + TP53 672+2T>G (6)
FGF4 amplification + HRAS Q61R + TP53 672+2T>G (6)
KRAS G12C + PD-L1 overexpression (4)
KRAS mutation + PD-L1 expression (4)
CPS1 overexpression + KRAS mutation + STK11 mutation (3)
HER-2 amplification + KRAS G12D (3)
KEAP1 deletion + KRAS mutation (3)
PD-L1 overexpression + KRAS mutation (3)
EGFR exon 19 deletion + NRAS Q61K (3)
EGFR exon 19 deletion + KRAS mutation (2)
KRAS G12C + PD-L1 underexpression (2)
KRAS mutation + PD-L1 negative (2)
MSI-L/dMMR + KRAS G12V (2)
PD-L1 expression + NRAS Q61R + BRAF D594N (2)
AXL overexpression + KRAS G12C (1)
CDH2 overexpression + KRAS wild-type (1)
Chr t(11;14) + KRAS mutation (1)
EGFR C797S + KRAS amplification + RB1 deletion (1)
EGFR L858R + KRAS amplification + RB1 deletion (1)
EGFR T790M + KRAS amplification + RB1 deletion (1)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)
EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)
EGFR expression + KRAS G12C (1)
EGFR overexpression + KRAS 13D (1)
EGFR overexpression + KRAS mutation (1)
FGFR1 overexpression + KRAS G12C (1)
GNA13 deletion + KRAS mutation (1)
GOPC-ROS1 fusion + KRAS Q61H (1)
HER-2 amplification + KRAS exon 2 wild-type (1)
HER-2 amplification + KRAS wild-type (1)
HER-2 overexpression + KRAS wild-type (1)
IGF1R overexpression + KRAS mutation (1)
IR overexpression + KRAS mutation (1)
IRS2 amplification + KRAS mutation (1)
KEAP1 mutation + KRAS wild-type (1)
KRAS A146 + TMB-H (1)
KRAS G12C + PD-L1 expression (1)
KRAS G12C + PD-L1 underexpression + STK11 mutation (1)
KRAS G12D + Chr del(9)(p21) (1)
KRAS G12D + HER-2 amplification + TMB-H (1)
KRAS G12D + TP53 deletion (1)
KRAS amplification + BRAF wild-type (1)
KRAS amplification + RAS wild-type (1)
KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)
KRAS mutation + BCL2A1 overexpression (1)
KRAS mutation + CDK9 overexpression + HR positive (1)
KRAS mutation + EGFR amplification (1)
KRAS mutation + ER expression (1)
KRAS mutation + HER-2 positive (1)
KRAS mutation + HR positive (1)
KRAS mutation + PD-L1 underexpression (1)
KRAS mutation + PIK3CA wild-type (1)
KRAS mutation + PTPN11 overexpression (1)
KRAS mutation + TP53 mutation + GNA13 deletion (1)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)
KRAS mutation + YKL-40 overexpression (1)
KRAS wild-type + BRAF V600E (1)
KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)
KRAS mutation + STK11 mutation + AXL expression (1)
MLL-AFF1 fusion + KRAS mutation (1)
MSI-H/dMMR + KRAS G12D (1)
MSI-H/dMMR + KRAS Mutation (1)
MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)
MTAP deletion + KRAS G12C (1)
PD-L1 negative + KRAS G12C (1)
PD-L1 overexpression + KRAS G12C + TP53 mutation (1)
POMK-NRG1 fusion + KRAS mutation (1)
POMK‐NRG1 fusion + KRAS G12D (1)
PTEN deletion + KRAS G12C (1)
RET positive + KRAS G12V (1)
ROS1 fusion + KRAS G12C (1)
STK11 mutation + KRAS mutation + TP53 deletion (1)
STRN-ALK fusion + KRAS G13D (1)
TP53 S12F + KRAS G12D + TMB-L (1)
CDKN2A Negative + NRAS Mutation (1)
Chr t(11;14) + NRAS mutation (1)
MLL-AFF1 fusion + NRAS mutation (1)
NRAS mutation + BRAF wild-type (1)
NRAS wild-type + NOTCH4 mutation (1)
HRAS Q61R + TP53 P278S + PD-L1 overexpression (1)
HRAS overexpression + PIK3CA amplification (1)
HRAS overexpression + PIK3CA mutation (1)
HER-2 amplification + KRAS G12C (0)
PRMT5 overexpression + KRAS mutation (0)
STK11 deletion + KRAS mutation (6)
FGF19 amplification + HRAS Q61R + TP53 672+2T>G (6)
FGF3 amplification + HRAS Q61R + TP53 672+2T>G (6)
FGF4 amplification + HRAS Q61R + TP53 672+2T>G (6)
KRAS G12C + PD-L1 overexpression (4)
KRAS mutation + PD-L1 expression (4)
CPS1 overexpression + KRAS mutation + STK11 mutation (3)
HER-2 amplification + KRAS G12D (3)
KEAP1 deletion + KRAS mutation (3)
PD-L1 overexpression + KRAS mutation (3)
EGFR exon 19 deletion + NRAS Q61K (3)
EGFR exon 19 deletion + KRAS mutation (2)
KRAS G12C + PD-L1 underexpression (2)
KRAS mutation + PD-L1 negative (2)
MSI-L/dMMR + KRAS G12V (2)
PD-L1 expression + NRAS Q61R + BRAF D594N (2)
AXL overexpression + KRAS G12C (1)
CDH2 overexpression + KRAS wild-type (1)
Chr t(11;14) + KRAS mutation (1)
EGFR C797S + KRAS amplification + RB1 deletion (1)
EGFR L858R + KRAS amplification + RB1 deletion (1)
EGFR T790M + KRAS amplification + RB1 deletion (1)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)
EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)
EGFR expression + KRAS G12C (1)
EGFR overexpression + KRAS 13D (1)
EGFR overexpression + KRAS mutation (1)
FGFR1 overexpression + KRAS G12C (1)
GNA13 deletion + KRAS mutation (1)
GOPC-ROS1 fusion + KRAS Q61H (1)
HER-2 amplification + KRAS exon 2 wild-type (1)
HER-2 amplification + KRAS wild-type (1)
HER-2 overexpression + KRAS wild-type (1)
IGF1R overexpression + KRAS mutation (1)
IR overexpression + KRAS mutation (1)
IRS2 amplification + KRAS mutation (1)
KEAP1 mutation + KRAS wild-type (1)
KRAS A146 + TMB-H (1)
KRAS G12C + PD-L1 expression (1)
KRAS G12C + PD-L1 underexpression + STK11 mutation (1)
KRAS G12D + Chr del(9)(p21) (1)
KRAS G12D + HER-2 amplification + TMB-H (1)
KRAS G12D + TP53 deletion (1)
KRAS amplification + BRAF wild-type (1)
KRAS amplification + RAS wild-type (1)
KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)
KRAS mutation + BCL2A1 overexpression (1)
KRAS mutation + CDK9 overexpression + HR positive (1)
KRAS mutation + EGFR amplification (1)
KRAS mutation + ER expression (1)
KRAS mutation + HER-2 positive (1)
KRAS mutation + HR positive (1)
KRAS mutation + PD-L1 underexpression (1)
KRAS mutation + PIK3CA wild-type (1)
KRAS mutation + PTPN11 overexpression (1)
KRAS mutation + TP53 mutation + GNA13 deletion (1)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)
KRAS mutation + YKL-40 overexpression (1)
KRAS wild-type + BRAF V600E (1)
KRAS wild-type + NRAS wild-type + MSI-H/dMMR (1)
KRAS mutation + STK11 mutation + AXL expression (1)
MLL-AFF1 fusion + KRAS mutation (1)
MSI-H/dMMR + KRAS G12D (1)
MSI-H/dMMR + KRAS Mutation (1)
MSI-H/dMMR + KRAS wild-type + BRAF wild-type (1)
MTAP deletion + KRAS G12C (1)
PD-L1 negative + KRAS G12C (1)
PD-L1 overexpression + KRAS G12C + TP53 mutation (1)
POMK-NRG1 fusion + KRAS mutation (1)
POMK‐NRG1 fusion + KRAS G12D (1)
PTEN deletion + KRAS G12C (1)
RET positive + KRAS G12V (1)
ROS1 fusion + KRAS G12C (1)
STK11 mutation + KRAS mutation + TP53 deletion (1)
STRN-ALK fusion + KRAS G13D (1)
TP53 S12F + KRAS G12D + TMB-L (1)
CDKN2A Negative + NRAS Mutation (1)
Chr t(11;14) + NRAS mutation (1)
MLL-AFF1 fusion + NRAS mutation (1)
NRAS mutation + BRAF wild-type (1)
NRAS wild-type + NOTCH4 mutation (1)
HRAS Q61R + TP53 P278S + PD-L1 overexpression (1)
HRAS overexpression + PIK3CA amplification (1)
HRAS overexpression + PIK3CA mutation (1)
HER-2 amplification + KRAS G12C (0)
PRMT5 overexpression + KRAS mutation (0)
›
Associations
(17)
News
Trials
Search handles
@ArndtVogel
@Aydah_AlAwadhi
@BenWestphalen
@BrunoBockorny
@CathyEngMD
@DrBonillaOnc
@DrChoueiri
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@GIcancerDoc
@HHorinouchi
@HKennecke
@JohnRTMonsonMD
@MLPOncoData
@MPishvaian
@Rndubois
@ShaalanBeg
@StephenVLiu
@SyedAAhmad5
@VanMorrisMD
@VivekSubbiah
@aparna1024
@bmassutis
@cancerassassin1
@drkpavithran
@fernandbteich
@helops79
@jgong15
@jonathanloree
@marklewismd
@p_ciracimd
@pashtoonkasi
@ramyathota1
@scottrberry
@weldeiry
@weoncologists
Search handles
@ArndtVogel
@Aydah_AlAwadhi
@BenWestphalen
@BrunoBockorny
@CathyEngMD
@DrBonillaOnc
@DrChoueiri
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@GIcancerDoc
@HHorinouchi
@HKennecke
@JohnRTMonsonMD
@MLPOncoData
@MPishvaian
@Rndubois
@ShaalanBeg
@StephenVLiu
@SyedAAhmad5
@VanMorrisMD
@VivekSubbiah
@aparna1024
@bmassutis
@cancerassassin1
@drkpavithran
@fernandbteich
@helops79
@jgong15
@jonathanloree
@marklewismd
@p_ciracimd
@pashtoonkasi
@ramyathota1
@scottrberry
@weldeiry
@weoncologists
Filter by
Latest
9ms
#Tucatinib + #Trastuzumab was approved earlier this year for refractory mCRC HER 2 positive disease. Previously, we had also discussed the implications of anti-egfr therapy w/ @GIcancerDoc and @CathyEngMD in this subset + RAS WT. This study by @GIcancerDoc continues to support:… https://t.co/16FDqtJdMS (@OncBrothers)
9 months ago
HER-2 positive • RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
10ms
Optimal maintenance strategy following FOLFOX + anti-EGFR in RAS WT mCRC: individual patient data pooled analysis of 4 clinical trials @OncologyAdvance https://t.co/m0C5Z9Vc3S 👉Low evidence, overall FU/LV + anti-EGFR preferred maintenance, stop & go stillan option @myESMO… https://t.co/VaNKlHpNf3 (@ArndtVogel)
10 months ago
Retrospective data
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
5-fluorouracil • leucovorin calcium
10ms
Panitumumab plus TAS as anti-EGFR rechallenge therapy in refractory RAS WT #CRC: OS & subgroup analysis of the randomized VELO trial at #WCGIC2023 👉rechallenge with anti-EGFR seems to be effective 👉PFS improved 👉no OS benefit, but 50% crossover @WCGIC @myESMO @OncoAlert (@ArndtVogel)
10 months ago
Clinical
|
RAS wild-type
|
Vectibix (panitumumab)
10ms
#OpenAccess from @FoundationATCG Genomic landscape of clinically advanced KRAS wild-type #PancreaticCancer Approximately 8% of pancreatic cancers are KRAS wild type, and many harbor actionable alterations. https://t.co/OmpTdg0OYU (@Aiims1742)
10 months ago
Clinical • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
11ms
BI-2493 / BI-2865: non-covalent inhibitors, binding the inactive state of KRAS, blocked the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. @Boehringer #LCSM https://t.co/7m549MX20c (@HHorinouchi)
11 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12A • KRAS G12 • KRAS G13 • KRAS Q61H • KRAS A146V • KRAS G13C
|
BI-2493
11ms
.@StintzingS joins us to chat about the results of the phase III FIRE-4 study designed for patients with metastatic colorectal cancer with RAS wild-type tumours. Watch the full discussion here: https://t.co/0yd9ACOnpD #ASCO2023 #Oncology #CancerCare #ColorectalCancer (@OncEd)
11 months ago
Clinical • Metastases
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
11ms
While we wait for better quality pics.. 😉 @VerastemOncolog @BanerjeeSusana @ASCO #ASCO23 RAMP201 #LGSOC #ovariancancer Phenomenal efficacy, safety data ▪︎RAF-MEK clamp avutometinib/ FAKi Defactinib. •Confirmed ORR 45% •KRASm 60% •KRAS WT 29% •(Unconfirmed ORR 52%-73%-29%) https://t.co/X6u3De05v4 (@CrozrX)
11 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
|
avutometinib (VS-6766) • defactinib (VS-6063)
11ms
Dr. Osumi from the super productive Japanese GOZILA team investigating the incidence and predictors for Neo RAS wild-type mCRC -NGS in CRC not static after all! #ASCO2023 #ASCO23 @KristenCiombor (@OncLive)
11 months ago
Next-generation sequencing
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
11ms
@StintzingS PhIII FIRE-4 #1L RAS WT #mCRC 13% RAS MT/7% BRAF MT in liquid bx despite WT on tissue predicts ORR, PFS, OS w/double WT on baseline liquid+tissue NGS w/FOLFIRI+cetux +/- switch maint. 19.4% emerging RAS mt w/cont cetux med 48.3 wks exposure w/no OS impact @OncoAlert (@jgong15)
11 months ago
Next-generation sequencing
|
BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
5-fluorouracil • irinotecan • leucovorin calcium
11ms
Now at #ASCO23: Dr. @gandhi_shipra on DC vaccine/pembro to address unmet need for patients with asymptomatic brain-metastatic #TNBC or HER2+ #breastcancer, and Dr. Rachel Frascati sharing promising findings on CIMAvax/nivo for patients with wild-type KRAS #NSCLC #lungcancer (@RoswellPark)
11 months ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
|
Keytruda (pembrolizumab) • Opdivo (nivolumab)
11ms
Dr. Raghav presenting awaiting data from DESTINY CRC02 in HER2+ mCRC; different doses of trastuzumab deruxtecan explored, and pts with RAS wt/mutant tumors both included #ASCO2023 #ASCO23 @KristenCiombor (@OncLive)
11 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • RAS (Rat Sarcoma Virus)
|
RAS mutation • RAS wild-type
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
11ms
A new randomized trial compares panitumumab and bevacizumab added to standard first-line chemotherapy for patients with left-sided, RAS wild-type metastatic colorectal cancer. https://t.co/OwrANFn49A @ILSONDavid #ColorectalCancer (@JWatch)
11 months ago
Clinical • Metastases
|
RAS wild-type
|
Avastin (bevacizumab) • Vectibix (panitumumab)
11ms
A new randomized trial compares panitumumab and bevacizumab added to standard first-line chemotherapy for patients with left-sided, RAS wild-type metastatic colorectal cancer. https://t.co/OwrANFn49A @ILSONDavid #ColorectalCancer (@JWatch)
11 months ago
Clinical • Metastases
|
RAS wild-type
|
Avastin (bevacizumab) • Vectibix (panitumumab)
12ms
Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift @JAMAOnc https://t.co/tbZq9QsiHt (@SyedAAhmad5)
12 months ago
RAS wild-type
12ms
👇🏾Here’s a personalized Share Link – a URL providing 50 days' free access to the article🙌🏾 “Tucatinib plus trastuzumab for chemotherapy-refractory, HER2➕, RAS wild-type unresectable/metastatic colorectal cancer (MOUNTAINEER): phase 2 📚” 🙏🏽 @RueschCenter for 🔦 on our study. (@pashtoonkasi)
12 months ago
P2 data • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
12ms
Tucatinib plus trastuzumab is a new treatment option for chemotherapy-refractory HER2-positive/RAS wild-type metastatic colorectal cancer-MOUNTAINEER https://t.co/GX61FjXMH7 (@drkpavithran)
12 months ago
Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • RAS wild-type • RAS wild-type + HER-2 positive
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
12ms
#OpenAccess in @ESMO_Open Smaller panel, similar results: genomic profiling and molecularly informed therapy in #PancreaticCancer By @SivekeJ eat al https://t.co/oulUjClhIZ Reiterating the importance of chasing down KRAS wild type cases for alternative actionable drivers. (@Aiims1742)
12 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
12ms
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study https://t.co/TWKHcuKxmh (@MLPOncoData)
12 months ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • RAS wild-type • RAS wild-type + HER-2 positive
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
12ms
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study https://t.co/OIScF6HZMS (@weldeiry)
12 months ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • RAS wild-type • RAS wild-type + HER-2 positive
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
12ms
🔥Tucatinib + trastuzumab for chemotherapy-refractory, HER2+, RAS WT #colorectalcancer🔥 🧐MOUNTAINEER 🌎phs-II, 117 pts @TheLancetOncol https://t.co/1b4G76uxxa ✅ORR 38% PFS 8,2 mo mOS 24 mo 👉The „next“ level for Her2 🎯💊!? -> now validation in phs-III @myESMO @OncoAlert https://t.co/lTXbE2bTTT (@ArndtVogel)
12 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
|
RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
12ms
🔥Tucatinib + trastuzumab for chemotherapy-refractory, HER2+, RAS WT #colorectalcancer🔥 🧐MOUNTAINEER 🌎phs-II, 117 pts @TheLancetOncol https://t.co/1b4G76uxxa ✅ORR 38% PFS 8,2 mo mOS 24 mo 👉The „next“ level for Her2 🎯💊!? -> now validation in phs-III @myESMO @OncoAlert (@ArndtVogel)
12 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
|
RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
12ms
👇🏾Here’s a personalized Share Link – a personalized URL providing 50 days' free access to the article🙌🏾 “Tucatinib plus trastuzumab for chemotherapy-refractory, HER2➕, RAS wild-type unresectable/metastatic colorectal cancer (MOUNTAINEER): phase 2 📚” https://t.co/CKqGOLxdlw (@pashtoonkasi)
12 months ago
Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
12ms
🎯 Consensus molecular subtypes are prognostic & predictive #biomarkers for panitumumab/flurouraciil/folinic acid maintenance in RAS WT #ColorectalCancer in the PanaMa #ClinicalTrial ➡️ https://t.co/46LUif16kx #CRCSM @ArndtStahler (@JCO_ASCO)
12 months ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
Vectibix (panitumumab) • leucovorin calcium
12ms
In Sydney, Australia 🇦🇺 to launch STELLAR 303 in Asia & Pacific countries. Testing XL-092+Atezolizumab in chemo refractory MSS #crcsm. Multiple endpoints to tackle including RAS wild type & site of metastasis 💫 @OncoAlert @ExelixisInc https://t.co/9HVFYIhzH4 (@AnwaarSaeed3)
12 months ago
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
Tecentriq (atezolizumab) • zanzalintinib (XL092)
1year
MORE is better?Panitumumab vs Bevacizumab and Survival in Patients With RAS Wild-type, Left-Sided Colorectal Cancer https://t.co/AWXP9I73Zu via @JAMA_current part of @JAMANetwork @Dr_M_Tejani @drzakoncology (@JohnRTMonsonMD)
1 year ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
Avastin (bevacizumab) • Vectibix (panitumumab)
1year
Panitumumab vs Bevacizumab and Survival in Patients With RAS Wild-type, Left-Sided Colorectal Cancer https://t.co/YOHFdVjKSi via @JAMA_current part of @JAMANetwork (@bmassutis)
1 year ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
Avastin (bevacizumab) • Vectibix (panitumumab)
1year
What about right sided RAS wild type dMMR mCRC? (@OFDM_FSK)
1 year ago
RAS (Rat Sarcoma Virus)
|
MSI-H/dMMR • RAS wild-type
1year
🔥BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features &Therapeutic Opportunities @AACR https://t.co/lRnVm3qUQ9 👉enriched in KRAS WT (10% of cases) 👉V600E , N486-P490 deletions & fusions (2-4%) 👉💊🎯for BRAFi, MEKi & combinations.. case reports.. @myESMO @OncoAlert (@ArndtVogel)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type
1year
@smitha42 very elegantly shared the data and her thoughts about treating left sided RAS Wild type mCRC! #GDUGI23 @NVijayvergiaMD @SoniaKupfer @CathyEngMD @GreatDebatesCME (@helops79)
1 year ago
RAS (Rat Sarcoma Virus)
|
RAS wild-type
1year
Great talk by @NVijayvergiaMD #GDUGI23 on the debate of the best regimen for left-sided RAS wild type mCRC! @GreatDebatesCME @CathyEngMD @smitha42 @SoniaKupfer (@helops79)
1 year ago
RAS (Rat Sarcoma Virus)
|
RAS wild-type
1year
The immune contexture of younger onset #PancreaticCancer is also quite distinct (based on bulk transcriptome profiling & deconvolution). The enrichment for RAS WT tumors & alternative drivers is a consistent finding in this age group. @PancPathologist https://t.co/RYtqjsWmir (@Aiims1742)
1 year ago
RAS (Rat Sarcoma Virus)
|
RAS wild-type
1year
Preprint using @carisls multi-omics profiling data by @DrJashDatta et al reports how young onset #PancreaticCancer is distinct at genomic & transcriptomic level from “usual” age of onset disease. https://t.co/kDtAFdmmEm Higher prevalence of KRAS WT disease & alternative drivers. (@Aiims1742)
1 year ago
Preprint
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
1year
A 7-5 📌 In RAS WT CRC patients, testing for RAS mutations at progression on tx with EGFRi is imp--these indicate resistant clones 📌With EGFRi re-challenge after the resistant clones have disappeared, EGFRi can work again! https://t.co/d5OzE0Jezz #CRCTrialsChat @OncoAlert (@jonathanloree)
1 year ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
EGFR mutation • RAS mutation • RAS wild-type
1year
#PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME (AMA & MOC) 🔗https://t.co/CRWgzGDAf7 🔬Path results for 62yo 👨🏾🦳 with left-sided, metastatic #ColonCancer (unresectable liver mets) who has undergone 1 cycle of FOLFOX: disease is KRAS wild type 🧐What would you add to tx regimen? (@RischZack)
1 year ago
Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
|
5-fluorouracil • leucovorin calcium
1year
16/22 #TumorBoardTuesday #GI23 👩🏻🏫Mini tweetorial 11👨🏻🏫 ✨VELO 📌EGFR rechallenge 📍Ph II RCT 62 pts: RAS WT mCRC on 3L; prior EGFR response & ≥4 mos EGFR break TAS-102 v TAS -102 + PAM mPFS: 4 mos💪🏽B v 2.5 mos💪🏽A (HR): 0.48; 95% CI 0.28-0.82; P = 0.007) 📚https://t.co/cUbSoaicVG (@RischZack)
1 year ago
Clinical
|
EGFR (Epidermal growth factor receptor) • RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
Lonsurf (trifluridine/tipiracil)
1year
@EileenMOReilly dawn of #KRAS inh’s beyond #G12C, young onset #PDAC w/signal of KRAS WT, #KRAS WT #pancsm exquisitely targetable, & building on #POLO maintenance concept in #DDR #PancreaticCancer Now at @CSCancerCenter 4th Annual GI Tumor conf https://t.co/7s8rEqg0r4 @OncoAlert (@jgong15)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS wild-type • RAS wild-type • KRAS G12
1year
Bev or antiEGFRs as upfront treatment of RAS wt mCRC patients? The answer is in the primary side ➡️ here our updated meta-analyses https://t.co/RLMZpgDqiE #oncotwitting #mCRC @IlBuonRossini @ChiaraCrem1 (@boccaccina)
1 year ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
1year
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients https://t.co/EWxWFq2XVv (@p_ciracimd)
1 year ago
Clinical • Metastases
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
1year
Today, the #FDA granted accelerated approval to tucatinib & trastuzumab for patients with RAS wild-type HER2 #mCRC. Here, Tanios S. Bekaii-Saab, MD, FACP, discusses what to expect if data from the MOUNTAINEER-03 study are positive. @GIcancerDoc @MayoClinic https://t.co/sDCamJD51Y (@TargetedOnc)
1 year ago
Clinical • FDA event
|
HER-2 (Human epidermal growth factor receptor 2) • RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
1year
Panitumumab Plus mFOLFOX6 Improves Survival in RAS Wild-Type mCRC https://t.co/AHd88wLylk vía @onclive (@dr_javr)
1 year ago
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium
1year
L sided mCRC RAS WT, Her2 FISH positive. How do you plan to sequence Rx outside CT? A. AntiEGFR upfront & Tucatinib/Trast ≥ 2L (as approved)? B. Avoid AntiEGFR & would consider using Tuc/Tras sooner? #crcsm @BijoyTelivala @RenoHemonc @HosseinTaghiz11 @OncoAlert @aparna1024 (@OncBrothers)
1 year ago
HER-2 (Human epidermal growth factor receptor 2) • RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
Tukysa (tucatinib)
1year
Absolutely critical not to miss KRAS wildtype #PancreaticCancer as this subgroup (of differing size) often has valuable targeted treatment options available to them. #pancsm 💜 (@BenWestphalen)
1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login